FDA Eyes Pill Pipelines to Sniff Out Fake Meds
Published Date: 5/1/2025
Notice
Summary
The FDA is asking for approval to collect info about how medicines move through the supply chain to keep drugs safe and real. This affects drug makers, distributors, and pharmacies who must share certain details to track medicines better. The goal? Make sure your meds are legit without causing big delays or extra costs.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Supply-Chain Data Sharing Duty
If you run or work for a drug maker, distributor, or pharmacy, you must share certain details about how medicines move through the supply chain so drugs can be tracked better. The FDA is seeking approval to collect that information under the Paperwork Reduction Act.
Stronger Assurance Medicines Are Legit
You will benefit from better tracking of how medicines move through the supply chain because the FDA is collecting information to keep drugs safe and real. The agency says the goal is to ensure your medicines are legitimate while not causing big delays or extra costs.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20063, Request for Nominations for Voting Members of Food and Drug Administration Advisory Committees
The FDA is looking for smart, qualified people to join its advisory committees and help make important decisions about food and drugs. If you have the right skills, you can apply anytime, but get your nomination in by November 30, 2026, for the best chance at current openings. This is a great chance to influence public health without any cost to you!
Previous / Next Documents
Previous: 2025-07568, Agency Information Collection Activities; Proposed Collection; Comment Request; Public Health Service Guideline on Infectious Disease Issues in Xenotransplantation
The FDA wants your thoughts on collecting info about infectious disease risks in xenotransplantation—where animal organs might be used in humans. This affects researchers and healthcare folks working with these transplants. They’re asking for comments within 60 days to keep things safe and smooth, with no new costs expected.
Next: 2025-07571, Importer of Controlled Substances Application: Unither Manufacturing LLC
Unither Manufacturing LLC wants to get official permission to import certain controlled substances. This means they’ll be allowed to bring in specific drugs that are carefully regulated. If approved, this could affect companies and regulators keeping an eye on drug imports, with no immediate cost or timing changes announced.